Welcome to our dedicated page for Lakefront Biotherapeutics SEC filings (Ticker: GLPGF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Lakefront Biotherapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Lakefront Biotherapeutics's regulatory disclosures and financial reporting.
Galapagos NV reported that its Board of Directors created 1,750,000 subscription rights under a new employee incentive program called “Subscription Right Plan 2026.” Each subscription right entitles the holder to subscribe to one new Galapagos share, targeting current and future personnel of the company and its subsidiaries.
The company states that its total share capital is €356,444,938.61, with 65,897,071 securities conferring voting rights, equal to the total number of shares. In addition to the new plan, there are 13,338,810 subscription rights outstanding under other employee plans, and one subscription right issued to Gilead Therapeutics that can increase its shareholding to 29.9% of issued and outstanding shares after exercise. Galapagos notes it has no convertible bonds or non-voting shares outstanding.
Galapagos NV reported that its Board of Directors created 1,750,000 subscription rights under a new employee incentive program called “Subscription Right Plan 2026.” Each subscription right entitles the holder to subscribe to one new Galapagos share, targeting current and future personnel of the company and its subsidiaries.
The company states that its total share capital is €356,444,938.61, with 65,897,071 securities conferring voting rights, equal to the total number of shares. In addition to the new plan, there are 13,338,810 subscription rights outstanding under other employee plans, and one subscription right issued to Gilead Therapeutics that can increase its shareholding to 29.9% of issued and outstanding shares after exercise. Galapagos notes it has no convertible bonds or non-voting shares outstanding.
Galapagos NV has appointed Tania Philipp as Chief Human Resources Officer, effective March 4, 2026. She will also join the Management Committee, reflecting her senior role in shaping the company’s people strategy.
Philipp succeeds Annelies Missotten, who will remain with Galapagos through June 30, 2026 to support a smooth transition. Philipp brings nearly three decades of executive-level HR experience in life sciences, including roles at Vor Bio, Tango Therapeutics and Bavarian Nordic. Galapagos describes itself as a biotechnology company focused on acquiring and advancing medicines in oncology and immunology & inflammation for serious diseases with unmet need.
Galapagos NV has appointed Tania Philipp as Chief Human Resources Officer, effective March 4, 2026. She will also join the Management Committee, reflecting her senior role in shaping the company’s people strategy.
Philipp succeeds Annelies Missotten, who will remain with Galapagos through June 30, 2026 to support a smooth transition. Philipp brings nearly three decades of executive-level HR experience in life sciences, including roles at Vor Bio, Tango Therapeutics and Bavarian Nordic. Galapagos describes itself as a biotechnology company focused on acquiring and advancing medicines in oncology and immunology & inflammation for serious diseases with unmet need.
Galapagos NV reported that Bank of America Corporation and affiliates crossed the 5% major shareholding threshold under Belgian transparency rules through transactions in Galapagos voting rights and equivalent financial instruments. On February 26, 2026 they first moved above 5%, then adjusted their position the following day.
As of March 2, 2026, Bank of America and its affiliates held 292,642 voting rights and 3,491,679 equivalent financial instruments, together representing 5.74% of Galapagos’ 65,897,071 outstanding shares. The notifications detail holdings across several entities, including BofA Securities and Merrill Lynch International, using instruments such as rights to recall, rights of use, options, and swaps.
Galapagos NV reported that Bank of America Corporation and affiliates crossed the 5% major shareholding threshold under Belgian transparency rules through transactions in Galapagos voting rights and equivalent financial instruments. On February 26, 2026 they first moved above 5%, then adjusted their position the following day.
As of March 2, 2026, Bank of America and its affiliates held 292,642 voting rights and 3,491,679 equivalent financial instruments, together representing 5.74% of Galapagos’ 65,897,071 outstanding shares. The notifications detail holdings across several entities, including BofA Securities and Merrill Lynch International, using instruments such as rights to recall, rights of use, options, and swaps.
Galapagos NV reported full-year 2025 results and described a major strategic reset toward a business development-led model. Total net revenues rose to €1,112.2 million, largely driven by releasing €1,069.0 million of deferred income from its collaboration with Gilead, leading to operating profit of €295.1 million and net profit of €320.9 million.
The company is winding down its cell therapy activities, recording an impairment of €228.1 million and additional restructuring costs, and also reorganized its small molecule business. Despite these charges, year-end 2025 cash and financial investments remained high at €2,998.0 million. Management guides to be cash flow neutral to positive by the end of 2026 and expects year-end 2026 cash between €2.775 and €2.850 billion, while shrinking to about 35–40 employees and focusing on transformative deals in oncology and immunology.
Galapagos NV reported full-year 2025 results and described a major strategic reset toward a business development-led model. Total net revenues rose to €1,112.2 million, largely driven by releasing €1,069.0 million of deferred income from its collaboration with Gilead, leading to operating profit of €295.1 million and net profit of €320.9 million.
The company is winding down its cell therapy activities, recording an impairment of €228.1 million and additional restructuring costs, and also reorganized its small molecule business. Despite these charges, year-end 2025 cash and financial investments remained high at €2,998.0 million. Management guides to be cash flow neutral to positive by the end of 2026 and expects year-end 2026 cash between €2.775 and €2.850 billion, while shrinking to about 35–40 employees and focusing on transformative deals in oncology and immunology.
Galapagos NV filed a report announcing that Dr. Paulo Fontoura has been appointed by way of co-optation as a Non-Executive Independent Director to its Board of Directors, effective February 9, 2026. He replaces Dr. Susanne Schaffert, who stepped down from the Board on November 1, 2025.
Dr. Fontoura has 20 years of pharmaceutical industry experience across neurology, immunology, ophthalmology, and rare diseases. He currently serves as Chief Medical Officer at Xaira and previously led clinical development in multiple therapeutic areas at Roche, with academic roots in neuroimmunology and ongoing teaching roles in Europe.
Galapagos NV filed a report announcing that Dr. Paulo Fontoura has been appointed by way of co-optation as a Non-Executive Independent Director to its Board of Directors, effective February 9, 2026. He replaces Dr. Susanne Schaffert, who stepped down from the Board on November 1, 2025.
Dr. Fontoura has 20 years of pharmaceutical industry experience across neurology, immunology, ophthalmology, and rare diseases. He currently serves as Chief Medical Officer at Xaira and previously led clinical development in multiple therapeutic areas at Roche, with academic roots in neuroimmunology and ongoing teaching roles in Europe.
Galapagos reported that Bank of America Corporation crossed the 5% disclosure threshold in its shares under Belgian transparency rules. The change followed an acquisition of Galapagos voting rights and equivalent financial instruments on February 9, 2026.
As of February 11, 2026, Bank of America and affiliates held 104,522 direct voting rights and 3,415,894 equivalent financial instruments in Galapagos, representing together 5.34% of the company’s 65,897,071 outstanding shares. The notification formalizes Bank of America’s status as a significant shareholder.
Galapagos reported that Bank of America Corporation crossed the 5% disclosure threshold in its shares under Belgian transparency rules. The change followed an acquisition of Galapagos voting rights and equivalent financial instruments on February 9, 2026.
As of February 11, 2026, Bank of America and affiliates held 104,522 direct voting rights and 3,415,894 equivalent financial instruments in Galapagos, representing together 5.34% of the company’s 65,897,071 outstanding shares. The notification formalizes Bank of America’s status as a significant shareholder.